Assignee
SIGILON THERAPEUTICS INC
US·6 granted patents·25 pending applications·7 citations·filing 2017–2024
Top patents by PatentIndex Score
31 records- 0187US12162994B2Biocompatible hydrogel capsules and process for preparing sameSIGILON THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2024·2 cites·14 claims
- 0283US2025206893A1Biocompatible hydrogel capsules and process for preparing sameSIGILON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0380US12306081B2Apparatuses and methods for formation of particlesSIGILON THERAPEUTICS INC·Filed 2020·Granted May 20, 2025·1 cites·29 claims
- 0480US11945786B2Compounds, devices, and uses thereofSIGILON THERAPEUTICS INC·Filed 2017·Granted Apr 2, 2024·2 cites·11 claims
- 0578US12161760B2Implantable particles and related methodsSIGILON THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2024·2 cites·27 claims
- 0676US12522571B2Compounds, devices, and uses thereofSIGILON THERAPEUTICS INC·Filed 2023·Granted Jan 13, 2026·0 cites·12 claims
- 0772US2025235409A1Implantable particles and related methodsSIGILON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0861US2024307455A1Compositions, devices and methods for treating immune-mediated inflammatory diseasesSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0960US2025345279A1Covalently crosslinked polysaccharides and methods of use thereofSIGILON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1060US2025352573A1Covalently crosslinked polysaccharides and methods of use thereofSIGILON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1159US2025144174A1Compositions, devices, and methods for treating cns disordersSIGILON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1257US2024374507A1Compositions, devices and methods for inducing antigen-specific immune toleranceSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1356US2025066512A1Modified polysaccharide polymers and related compositions and methods thereofSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1456US2025136671A1Therapies for mucopolysaccharidosis type 6SIGILON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1555US2024123040A1Compositions, devices and methods for treating mps vi diseaseSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1655US2023287341A1Genetically modified cell lines expressing an exogenous substance and uses thereofSIGILON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1754US2025000788A1Biocompatible devices for cell-based therapies and related methodsSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1854US2023233679A1Compositions, devices and methods for inducing immune responses to infectious agentsSIGILON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1953US2023045277A1Compounds, polymers, devices, and uses thereofSIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2052US2023003706A1Methods of evaluating small molecule-modified polymers in compositionsSIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2152US2025017864A1Compositions for cell-based therapies and related methodsSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2252US2025084189A1Modified polysaccharide polymers and related compositions and methods thereofSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2351US2022349896A1Methods of evaluating polypeptide-modified polymers in compositionsSIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2450US2023303502A1Heteroaryl and heterocyclyl compoundsSIGILON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2549US2024209336A1Genetically modified human cell lines and uses thereofSIGILON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2647US2023123802A1Compositions, devices, and methods for factor vii therapySIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2746US2021145889A1Methods, compositions, and implantable elements comprising stem cellsSIGILON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2844US2022000789A1Implantable devices for cell therapy and related methodsSIGILON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2943US2022267794A1Compositions, devices, and methods for treating fabry diseaseSIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3041US12570955B2Monoclonal cell lines expressing an exogenous substance and uses thereofSIGILON THERAPEUTICS INC·Filed 2020·Granted Mar 10, 2026·0 cites·17 claims
- 3137US2020263196A1Methods, compositions, and implantable elements comprising active cellsSIGILON THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SIGILON THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →